JP2020505407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505407A5 JP2020505407A5 JP2019540570A JP2019540570A JP2020505407A5 JP 2020505407 A5 JP2020505407 A5 JP 2020505407A5 JP 2019540570 A JP2019540570 A JP 2019540570A JP 2019540570 A JP2019540570 A JP 2019540570A JP 2020505407 A5 JP2020505407 A5 JP 2020505407A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- composition according
- composition
- patient
- hexahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 108
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 claims description 96
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 claims description 96
- 239000003112 inhibitor Substances 0.000 claims description 89
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims description 57
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims description 57
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 230000004060 metabolic process Effects 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 25
- 239000012458 free base Substances 0.000 claims description 21
- 206010067484 Adverse reaction Diseases 0.000 claims description 20
- 208000000269 Hyperkinesis Diseases 0.000 claims description 20
- 230000006838 adverse reaction Effects 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 208000020016 psychiatric disease Diseases 0.000 claims description 16
- -1 isoquinoline-2-yl Chemical group 0.000 claims description 14
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 12
- 208000019022 Mood disease Diseases 0.000 claims description 9
- 230000000926 neurological effect Effects 0.000 claims description 9
- 201000000980 schizophrenia Diseases 0.000 claims description 9
- 206010001540 Akathisia Diseases 0.000 claims description 8
- 208000023105 Huntington disease Diseases 0.000 claims description 8
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 6
- 206010022437 insomnia Diseases 0.000 claims description 6
- 208000006820 Arthralgia Diseases 0.000 claims description 5
- 206010008748 Chorea Diseases 0.000 claims description 5
- 206010019233 Headaches Diseases 0.000 claims description 5
- 206010028813 Nausea Diseases 0.000 claims description 5
- 208000032140 Sleepiness Diseases 0.000 claims description 5
- 206010041349 Somnolence Diseases 0.000 claims description 5
- 206010044565 Tremor Diseases 0.000 claims description 5
- 206010047700 Vomiting Diseases 0.000 claims description 5
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 5
- 208000012601 choreatic disease Diseases 0.000 claims description 5
- 231100000869 headache Toxicity 0.000 claims description 5
- 230000008693 nausea Effects 0.000 claims description 5
- 230000008673 vomiting Effects 0.000 claims description 5
- 208000012661 Dyskinesia Diseases 0.000 claims description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 206010010219 Compulsions Diseases 0.000 claims description 3
- 208000027534 Emotional disease Diseases 0.000 claims description 3
- 208000027776 Extrapyramidal disease Diseases 0.000 claims description 3
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 206010026749 Mania Diseases 0.000 claims description 3
- 102000003946 Prolactin Human genes 0.000 claims description 3
- 108010057464 Prolactin Proteins 0.000 claims description 3
- 206010039424 Salivary hypersecretion Diseases 0.000 claims description 3
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 3
- 208000016620 Tourette disease Diseases 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 208000029560 autism spectrum disease Diseases 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000009251 neurologic dysfunction Effects 0.000 claims description 3
- 208000015015 neurological dysfunction Diseases 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 229940097325 prolactin Drugs 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 230000004584 weight gain Effects 0.000 claims description 3
- 235000019786 weight gain Nutrition 0.000 claims description 3
- 208000008630 Sialorrhea Diseases 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 64
- GEJDGVNQKABXKG-CFKGEZKQSA-N [(2r,3r,11br)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl] (2s)-2-amino-3-methylbutanoate Chemical compound C1CN2C[C@@H](CC(C)C)[C@H](OC(=O)[C@@H](N)C(C)C)C[C@@H]2C2=C1C=C(OC)C(OC)=C2 GEJDGVNQKABXKG-CFKGEZKQSA-N 0.000 description 28
- 229950006411 valbenazine Drugs 0.000 description 28
- 206010021034 Hypometabolism Diseases 0.000 description 21
- MLAYZCMWRNQKQX-UHFFFAOYSA-N 2-hydroxy-1h-isoquinoline Chemical compound C1=CC=C2C=CN(O)CC2=C1 MLAYZCMWRNQKQX-UHFFFAOYSA-N 0.000 description 14
- 230000036470 plasma concentration Effects 0.000 description 8
- 206010003591 Ataxia Diseases 0.000 description 2
- 208000012639 Balance disease Diseases 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 208000002033 Myoclonus Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022160831A JP2022174344A (ja) | 2017-01-27 | 2022-10-05 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2024092152A JP2024107168A (ja) | 2017-01-27 | 2024-06-06 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451605P | 2017-01-27 | 2017-01-27 | |
| US62/451,605 | 2017-01-27 | ||
| PCT/US2017/055980 WO2018140096A1 (en) | 2017-01-27 | 2017-10-10 | Methods for the administration of certain vmat2 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022160831A Division JP2022174344A (ja) | 2017-01-27 | 2022-10-05 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505407A JP2020505407A (ja) | 2020-02-20 |
| JP2020505407A5 true JP2020505407A5 (enExample) | 2020-11-19 |
| JP7199361B2 JP7199361B2 (ja) | 2023-01-05 |
Family
ID=62978647
Family Applications (16)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540570A Active JP7199361B2 (ja) | 2017-01-27 | 2017-10-10 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2019540568A Active JP7199360B2 (ja) | 2017-01-27 | 2017-10-10 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2019540557A Active JP7199359B2 (ja) | 2017-01-27 | 2017-10-10 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2019540650A Active JP7107950B2 (ja) | 2017-01-27 | 2017-10-10 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2020520311A Active JP7090151B2 (ja) | 2017-01-27 | 2017-10-10 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2022008580A Withdrawn JP2022040408A (ja) | 2017-01-27 | 2022-01-24 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2022113075A Withdrawn JP2022137219A (ja) | 2017-01-27 | 2022-07-14 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2022160177A Withdrawn JP2022174343A (ja) | 2017-01-27 | 2022-10-04 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2022160833A Withdrawn JP2022174345A (ja) | 2017-01-27 | 2022-10-05 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2022160831A Withdrawn JP2022174344A (ja) | 2017-01-27 | 2022-10-05 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2023149999A Pending JP2023161033A (ja) | 2017-01-27 | 2023-09-15 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2024092148A Pending JP2024107167A (ja) | 2017-01-27 | 2024-06-06 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2024092155A Pending JP2024107169A (ja) | 2017-01-27 | 2024-06-06 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2024092152A Pending JP2024107168A (ja) | 2017-01-27 | 2024-06-06 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2024093040A Active JP7828390B2 (ja) | 2017-01-27 | 2024-06-07 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2025126262A Pending JP2025146959A (ja) | 2017-01-27 | 2025-07-29 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
Family Applications After (15)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540568A Active JP7199360B2 (ja) | 2017-01-27 | 2017-10-10 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2019540557A Active JP7199359B2 (ja) | 2017-01-27 | 2017-10-10 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2019540650A Active JP7107950B2 (ja) | 2017-01-27 | 2017-10-10 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2020520311A Active JP7090151B2 (ja) | 2017-01-27 | 2017-10-10 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2022008580A Withdrawn JP2022040408A (ja) | 2017-01-27 | 2022-01-24 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2022113075A Withdrawn JP2022137219A (ja) | 2017-01-27 | 2022-07-14 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2022160177A Withdrawn JP2022174343A (ja) | 2017-01-27 | 2022-10-04 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2022160833A Withdrawn JP2022174345A (ja) | 2017-01-27 | 2022-10-05 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2022160831A Withdrawn JP2022174344A (ja) | 2017-01-27 | 2022-10-05 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2023149999A Pending JP2023161033A (ja) | 2017-01-27 | 2023-09-15 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2024092148A Pending JP2024107167A (ja) | 2017-01-27 | 2024-06-06 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2024092155A Pending JP2024107169A (ja) | 2017-01-27 | 2024-06-06 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2024092152A Pending JP2024107168A (ja) | 2017-01-27 | 2024-06-06 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2024093040A Active JP7828390B2 (ja) | 2017-01-27 | 2024-06-07 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP2025126262A Pending JP2025146959A (ja) | 2017-01-27 | 2025-07-29 | 特定のｖｍａｔ２インヒビターを投与するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (10) | US10874648B2 (enExample) |
| JP (16) | JP7199361B2 (enExample) |
| KR (14) | KR20200126430A (enExample) |
| CN (6) | CN116712434A (enExample) |
| AU (7) | AU2017395703B2 (enExample) |
| CA (5) | CA3051830A1 (enExample) |
| EA (5) | EA201991780A1 (enExample) |
| MX (6) | MX2020003462A (enExample) |
| MY (5) | MY199695A (enExample) |
| PH (6) | PH12022553251A1 (enExample) |
| SG (3) | SG11201906885TA (enExample) |
| WO (5) | WO2018140095A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115304596A (zh) | 2015-10-30 | 2022-11-08 | 纽罗克里生物科学有限公司 | Valbenazine盐及其多晶形物 |
| SI3394057T1 (sl) | 2015-12-23 | 2022-06-30 | Neurocrine Biosciences, Inc. | Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata) |
| MY199695A (en) | 2017-01-27 | 2023-11-18 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705305D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| DK3684333T3 (da) | 2017-09-21 | 2025-05-12 | Neurocrine Biosciences Inc | Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| US20200230127A1 (en) | 2017-10-10 | 2020-07-23 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
| JP7212958B2 (ja) | 2017-12-26 | 2023-01-26 | ▲蘇▼州科睿思制▲葯▼有限公司 | バルベナジントシル酸塩の結晶形及びその製造方法並びに用途 |
| AU2019261403B2 (en) | 2018-04-25 | 2025-05-15 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| US20200345663A1 (en) * | 2018-06-10 | 2020-11-05 | Axsome Therapeutics, Inc. | Methods of modulating tetrabenazine metabolites plasma levels using bupropion |
| BR112021000019A2 (pt) * | 2018-08-15 | 2021-04-06 | Neurocrine Biosciences Inc. | Métodos para administração de certos inibidores de vmat2 |
| IL321020A (en) * | 2019-05-09 | 2025-07-01 | Neurocrine Biosciences Inc | Methods of administering certain vmat2 inhibitors |
| WO2021030619A1 (en) * | 2019-08-14 | 2021-02-18 | F. Hoffmann-La Roche Ag | Methods of treating cancer |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| AU2020408557A1 (en) * | 2019-12-20 | 2022-08-11 | Eisai R&D Management Co., Ltd. | Use of lemborexant for treating insomnia |
| MX2023014977A (es) | 2021-06-30 | 2024-02-09 | Neurocrine Biosciences Inc | Valbenazina para usarse en el tratamiento de discinesia debido a paralisis cerebral. |
| EP4362944A1 (en) | 2021-06-30 | 2024-05-08 | Neurocrine Biosciences, Inc. | Valbenazine for use in the add-on treatment of schizophrenia |
| IL310584A (en) * | 2021-08-16 | 2024-04-01 | Foresee Pharmaceuticals Co Ltd | Depot polymer formulations for sustained release administration of VMAT2 inhibitors |
| US20250064990A1 (en) | 2021-08-20 | 2025-02-27 | Neurocrine Biosciences, Inc. | Methods of screening for vmat2 inhibitors |
| US20230100844A1 (en) * | 2021-09-10 | 2023-03-30 | ATAI Life Sciences AG | Ibogaine combination treatment |
| JP2024540082A (ja) * | 2021-10-29 | 2024-10-31 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | バルベナジン組成物 |
| IL315181A (en) | 2022-03-07 | 2024-10-01 | Neurocrine Biosciences Inc | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
| WO2024107925A1 (en) * | 2022-11-16 | 2024-05-23 | Foresee Pharmaceuticals Co., Ltd. | Depot compositions for vesicular monoamine transporter 2 (vmat2) inhibitors |
| WO2025038959A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025038938A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Valbenazine for use in the treatment of huntington's chorea |
| WO2025096823A1 (en) | 2023-11-01 | 2025-05-08 | Neurocrine Biosciences, Inc. | Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine |
| WO2025188830A1 (en) | 2024-03-06 | 2025-09-12 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1068938A (en) | 1910-11-07 | 1913-07-29 | Gustav F Schulze | Vehicle-apron. |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| JPS5283918A (en) | 1976-01-01 | 1977-07-13 | Wellcome Found | Pharmaceutical composition |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| JPS5777697A (en) | 1980-11-04 | 1982-05-15 | Nippon Zoki Pharmaceut Co Ltd | Physiologically active substance nsq |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| JPS57209225A (en) | 1981-06-18 | 1982-12-22 | Yamasa Shoyu Co Ltd | Antitumor activity intensifier |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| JPS6028987A (ja) | 1983-07-28 | 1985-02-14 | Chugai Pharmaceut Co Ltd | 新規ジゴキシン誘導体 |
| ES8702440A1 (es) | 1984-10-04 | 1986-12-16 | Monsanto Co | Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa. |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5204329A (en) | 1990-06-11 | 1993-04-20 | Du Pont Merck Pharmaceutical Company | Treatment of organ transplantation rejection |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| WO1997001331A2 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| ZA977967B (en) | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| AU722289B2 (en) | 1996-10-01 | 2000-07-27 | Aptalis Pharmatech, Inc. | Taste-masked microcapsule compositions and methods of manufacture |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| EP0839525B1 (en) | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| DE69719367T2 (de) | 1996-12-20 | 2003-10-16 | Takeda Chemical Industries, Ltd. | Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| WO2000024399A1 (en) | 1998-10-23 | 2000-05-04 | Sepracor Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| MXPA03001771A (es) | 2000-08-30 | 2003-06-04 | Pfizer Prod Inc | Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento. |
| EP1513403B1 (en) | 2002-05-28 | 2017-02-15 | Bette Pollard | Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders |
| WO2004026258A2 (en) | 2002-09-19 | 2004-04-01 | University Of Utah Research Foundation | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease |
| US7230097B2 (en) | 2003-03-10 | 2007-06-12 | Lupin Ltd. | Process for preparation of 7-[α-Amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid |
| GB0307259D0 (en) | 2003-03-28 | 2003-05-07 | Glaxo Group Ltd | Process |
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| BRPI0510915A (pt) | 2004-06-04 | 2007-11-13 | Genentech Inc | método para o tratamento da esclerose múltipla e artigo manufaturado |
| CA3113166A1 (en) | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| BRPI0517406A (pt) | 2004-10-28 | 2008-10-07 | Wyeth Corp | método de tratamento, controle ou redução do risco de uma infecção bacteriana e um estado de insuficiência cardìaca em um ser humano; método para controle do aumento dos nìveis plasmáticos de digoxina em estado constante em um ser humano; método de tratamento, controle ou redução do risco de uma infecção bacteriana com tigeciclina em um paciente; uso de tigeciclina em combinação com digoxina; e produto compreendendo tigeciclina e digoxina como uma preparação combinada |
| WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| EP1855677B1 (en) | 2005-08-06 | 2008-12-03 | Cambridge Laboratories (Ireland) Limited | 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses |
| US20100076087A1 (en) | 2005-10-06 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Methods of reduction of interpatient variability |
| EP2081929B1 (en) * | 2006-11-08 | 2013-01-09 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
| GB0721669D0 (en) | 2007-11-02 | 2007-12-12 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| BRPI0906962B8 (pt) | 2008-01-18 | 2021-05-25 | Eisai R&D Man Co Ltd | composto de aminodiidrotiazina fundido |
| US20110053866A1 (en) | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| WO2011019956A2 (en) | 2009-08-12 | 2011-02-17 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| GB2463452A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
| GB2463451A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia |
| EP3345905B1 (en) | 2008-09-18 | 2021-09-01 | Auspex Pharmaceuticals, Inc. | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
| US20100096319A1 (en) | 2008-10-17 | 2010-04-22 | General Electric Company | Separator assembly |
| HUE037724T2 (hu) | 2009-04-06 | 2018-09-28 | Vanda Pharmaceuticals Inc | Eljárás a KCNQ1 gén polimorfizmusán alapuló kezelésre |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012153341A1 (en) | 2011-05-12 | 2012-11-15 | Arch Pharmalabs Limited | A process for the preparation of iloperidone and pharmaceutically acceptable salts thereof |
| EP2897615A4 (en) * | 2012-09-18 | 2016-04-27 | Auspex Pharmaceuticals Inc | PHARMACOKINETIC FORMULATIONS OF DEUTERATED BENZOCHINOL INHIBITORS OF THE VESICLE MONOAMINE TRANSPORTER 2 |
| CA3158157A1 (en) * | 2012-12-18 | 2014-06-26 | Vanda Pharmaceuticals Inc. | Use of tasimelteon in the treatment of circadian rhythm disorders |
| US20160068526A1 (en) | 2013-01-31 | 2016-03-10 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2015077521A1 (en) | 2013-11-22 | 2015-05-28 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| MX2016009817A (es) | 2014-01-27 | 2017-02-28 | Auspex Pharmaceuticals Inc | Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2. |
| WO2015120317A1 (en) | 2014-02-07 | 2015-08-13 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
| WO2015120110A2 (en) | 2014-02-07 | 2015-08-13 | Auspex Pharmaceuticals, Inc. | Novel pharmaceutical formulations |
| KR20240011255A (ko) | 2014-05-06 | 2024-01-25 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 |
| CN107438606B (zh) | 2015-02-06 | 2020-09-18 | 纽罗克里生物科学有限公司 | [9,10-二甲氧基-3-(2-甲基丙基)-1h,2h,3h,4h,6h,7h,11bh-吡啶并-[2,1-a]异喹啉-2-基]甲醇及与其相关的化合物、组合物和方法 |
| WO2016144901A1 (en) | 2015-03-06 | 2016-09-15 | Auspex Pharmaceuticals, Inc. | Methods for the treatment of abnormal involuntary movement disorders |
| MX390795B (es) | 2015-06-23 | 2025-03-21 | Neurocrine Biosciences Inc | Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos. |
| CN115304596A (zh) | 2015-10-30 | 2022-11-08 | 纽罗克里生物科学有限公司 | Valbenazine盐及其多晶形物 |
| SI3394057T1 (sl) | 2015-12-23 | 2022-06-30 | Neurocrine Biosciences, Inc. | Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata) |
| WO2018102673A1 (en) | 2016-12-02 | 2018-06-07 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating schizophrenia or schizoaffective disorder |
| MY199695A (en) | 2017-01-27 | 2023-11-18 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| CN110691596A (zh) | 2017-04-01 | 2020-01-14 | 阿德普蒂奥制药有限公司 | 药物组合物 |
| CA3057543A1 (en) | 2017-04-01 | 2018-10-04 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| US10857144B2 (en) * | 2017-05-16 | 2020-12-08 | Bow River LLC | Methods of treatment |
| AU2017414697B2 (en) * | 2017-05-16 | 2020-03-05 | Bow River LLC | Methods of treatment |
| DK3684333T3 (da) | 2017-09-21 | 2025-05-12 | Neurocrine Biosciences Inc | Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| US20200230127A1 (en) | 2017-10-10 | 2020-07-23 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
| US11384077B2 (en) | 2017-11-22 | 2022-07-12 | Assia Chemical Industries Ltd. | Solid state form of Valbenazine |
| MX2020013004A (es) | 2018-06-14 | 2021-02-17 | Neurocrine Biosciences Inc | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. |
| BR112021000019A2 (pt) | 2018-08-15 | 2021-04-06 | Neurocrine Biosciences Inc. | Métodos para administração de certos inibidores de vmat2 |
| IL321020A (en) | 2019-05-09 | 2025-07-01 | Neurocrine Biosciences Inc | Methods of administering certain vmat2 inhibitors |
| US10689380B1 (en) | 2019-07-30 | 2020-06-23 | Farmhispania S.A. | Crystalline forms of valbenazine ditosylate |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
-
2017
- 2017-10-10 MY MYPI2019004296A patent/MY199695A/en unknown
- 2017-10-10 CA CA3051830A patent/CA3051830A1/en active Pending
- 2017-10-10 SG SG11201906885TA patent/SG11201906885TA/en unknown
- 2017-10-10 KR KR1020207030652A patent/KR20200126430A/ko not_active Ceased
- 2017-10-10 AU AU2017395703A patent/AU2017395703B2/en active Active
- 2017-10-10 KR KR1020257002855A patent/KR20250020722A/ko active Pending
- 2017-10-10 MY MYPI2019004292A patent/MY195934A/en unknown
- 2017-10-10 WO PCT/US2017/055965 patent/WO2018140095A2/en not_active Ceased
- 2017-10-10 CN CN202310682815.1A patent/CN116712434A/zh active Pending
- 2017-10-10 KR KR1020237041797A patent/KR20230170135A/ko not_active Ceased
- 2017-10-10 EA EA201991780A patent/EA201991780A1/ru unknown
- 2017-10-10 WO PCT/US2017/055907 patent/WO2018140093A1/en not_active Ceased
- 2017-10-10 CA CA3051829A patent/CA3051829A1/en active Pending
- 2017-10-10 EA EA202090676A patent/EA202090676A1/ru unknown
- 2017-10-10 EA EA201991782A patent/EA201991782A1/ru unknown
- 2017-10-10 KR KR1020197024657A patent/KR20190108149A/ko not_active Ceased
- 2017-10-10 KR KR1020257017150A patent/KR20250078629A/ko active Pending
- 2017-10-10 JP JP2019540570A patent/JP7199361B2/ja active Active
- 2017-10-10 MX MX2020003462A patent/MX2020003462A/es unknown
- 2017-10-10 KR KR1020207012774A patent/KR20200066662A/ko not_active Ceased
- 2017-10-10 CA CA3051832A patent/CA3051832C/en active Active
- 2017-10-10 US US16/481,033 patent/US10874648B2/en active Active
- 2017-10-10 KR KR1020237041673A patent/KR20230169457A/ko not_active Ceased
- 2017-10-10 KR KR1020257002858A patent/KR20250020723A/ko active Pending
- 2017-10-10 MY MYPI2020001816A patent/MY202219A/en unknown
- 2017-10-10 KR KR1020197024654A patent/KR20190108146A/ko not_active Ceased
- 2017-10-10 CA CA3078719A patent/CA3078719A1/en active Pending
- 2017-10-10 US US16/481,037 patent/US20200093808A1/en not_active Abandoned
- 2017-10-10 KR KR1020257002857A patent/KR20250022883A/ko active Pending
- 2017-10-10 US US16/481,029 patent/US20190381016A1/en not_active Abandoned
- 2017-10-10 EA EA201991786A patent/EA201991786A1/ru unknown
- 2017-10-10 MX MX2019008868A patent/MX393077B/es unknown
- 2017-10-10 CA CA3051834A patent/CA3051834C/en active Active
- 2017-10-10 CN CN201780088730.3A patent/CN110740731A/zh active Pending
- 2017-10-10 WO PCT/US2017/055980 patent/WO2018140096A1/en not_active Ceased
- 2017-10-10 CN CN201780097535.7A patent/CN111655034A/zh active Pending
- 2017-10-10 WO PCT/US2017/055877 patent/WO2018140092A1/en not_active Ceased
- 2017-10-10 CN CN201780088766.1A patent/CN110740732A/zh active Pending
- 2017-10-10 MY MYPI2019004293A patent/MY191077A/en unknown
- 2017-10-10 CN CN201780088736.0A patent/CN110709071A/zh active Pending
- 2017-10-10 JP JP2019540568A patent/JP7199360B2/ja active Active
- 2017-10-10 KR KR1020237007871A patent/KR20230038601A/ko not_active Ceased
- 2017-10-10 JP JP2019540557A patent/JP7199359B2/ja active Active
- 2017-10-10 WO PCT/US2017/055931 patent/WO2018140094A1/en not_active Ceased
- 2017-10-10 JP JP2019540650A patent/JP7107950B2/ja active Active
- 2017-10-10 AU AU2017395700A patent/AU2017395700B2/en active Active
- 2017-10-10 JP JP2020520311A patent/JP7090151B2/ja active Active
- 2017-10-10 KR KR1020197024656A patent/KR20190108148A/ko not_active Ceased
- 2017-10-10 EA EA201991784A patent/EA201991784A1/ru unknown
- 2017-10-10 PH PH1/2022/553251A patent/PH12022553251A1/en unknown
- 2017-10-10 MX MX2019008855A patent/MX394417B/es unknown
- 2017-10-10 MX MX2019008854A patent/MX394418B/es unknown
- 2017-10-10 KR KR1020237041798A patent/KR20230170136A/ko not_active Ceased
- 2017-10-10 AU AU2017395701A patent/AU2017395701B2/en active Active
- 2017-10-10 AU AU2017395702A patent/AU2017395702B2/en active Active
- 2017-10-10 CN CN201780088897.XA patent/CN110769826A/zh active Pending
- 2017-10-10 KR KR1020197024655A patent/KR20190108147A/ko not_active Ceased
- 2017-10-10 AU AU2017395704A patent/AU2017395704B8/en active Active
- 2017-10-10 MY MYPI2019004294A patent/MY203491A/en unknown
- 2017-10-10 SG SG11201906891RA patent/SG11201906891RA/en unknown
- 2017-10-10 SG SG11201906883SA patent/SG11201906883SA/en unknown
- 2017-10-10 MX MX2019008853A patent/MX394415B/es unknown
-
2019
- 2019-07-25 MX MX2022007141A patent/MX2022007141A/es unknown
- 2019-07-26 PH PH12019501740A patent/PH12019501740A1/en unknown
- 2019-07-26 PH PH12019501744A patent/PH12019501744A1/en unknown
- 2019-07-26 PH PH12019501734A patent/PH12019501734A1/en unknown
- 2019-07-26 PH PH12019501732A patent/PH12019501732A1/en unknown
-
2020
- 2020-04-08 PH PH12020550238A patent/PH12020550238A1/en unknown
- 2020-05-08 US US16/870,706 patent/US10857137B2/en active Active
- 2020-05-08 US US16/870,423 patent/US10952997B2/en active Active
- 2020-05-08 US US16/870,572 patent/US11040029B2/en active Active
- 2020-10-17 US US17/073,304 patent/US10912771B1/en active Active
- 2020-10-26 US US17/080,343 patent/US11439629B2/en active Active
- 2020-12-17 US US17/125,190 patent/US20210169862A1/en not_active Abandoned
-
2022
- 2022-01-24 JP JP2022008580A patent/JP2022040408A/ja not_active Withdrawn
- 2022-05-12 AU AU2022203201A patent/AU2022203201B2/en active Active
- 2022-05-17 AU AU2022203327A patent/AU2022203327A1/en not_active Abandoned
- 2022-07-14 JP JP2022113075A patent/JP2022137219A/ja not_active Withdrawn
- 2022-10-04 JP JP2022160177A patent/JP2022174343A/ja not_active Withdrawn
- 2022-10-05 JP JP2022160833A patent/JP2022174345A/ja not_active Withdrawn
- 2022-10-05 JP JP2022160831A patent/JP2022174344A/ja not_active Withdrawn
-
2023
- 2023-09-15 JP JP2023149999A patent/JP2023161033A/ja active Pending
-
2024
- 2024-06-06 JP JP2024092148A patent/JP2024107167A/ja active Pending
- 2024-06-06 JP JP2024092155A patent/JP2024107169A/ja active Pending
- 2024-06-06 JP JP2024092152A patent/JP2024107168A/ja active Pending
- 2024-06-07 JP JP2024093040A patent/JP7828390B2/ja active Active
-
2025
- 2025-04-23 US US19/186,745 patent/US20260048042A1/en active Pending
- 2025-07-29 JP JP2025126262A patent/JP2025146959A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505407A5 (enExample) | ||
| JP2020505408A5 (enExample) | ||
| JP2020536905A5 (enExample) | ||
| JP2020514318A5 (enExample) | ||
| US11666545B2 (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| CN107921032B (zh) | 用于治疗神经学疾病或病症的vmat2抑制剂 | |
| JP2020514317A5 (enExample) | ||
| JP2015519404A5 (enExample) | ||
| KR101793777B1 (ko) | 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 피라졸 유도체의 용도 | |
| KR20250029267A (ko) | 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 | |
| JP2012530779A5 (enExample) | ||
| JP2009526771A (ja) | 高投与量のミコフェノール酸（ｍｐａ） | |
| RU2017114933A (ru) | Соединения и композиции для лечения или профилактики патологических состояний, связанных с избыточным отложением фибрина и/или образованием тромбов | |
| JP2018522920A5 (enExample) | ||
| JP2011518168A5 (enExample) | ||
| JP2011526929A5 (enExample) | ||
| JPWO2008090736A1 (ja) | アルツハイマー型認知症の予防及び治療のための医薬 | |
| JPWO2021007245A5 (enExample) | ||
| RU2006135124A (ru) | Фармацевтические композиции толперизона контролируемого высвобождения, предназначенные для перорального введения | |
| EP3665701A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| JP5408261B2 (ja) | うつ病、不安、統合失調症、睡眠障害、及びてんかん治療のためのコハク酸のコリン塩 | |
| RU2010120806A (ru) | Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид | |
| JP2020520996A (ja) | フペルジンの放出調節医薬組成物およびその使用方法 | |
| JPS5823618A (ja) | 精神分裂症を治療する組成物 | |
| TW201235038A (en) | Sensitizer, kit and use for cancer therapy |